BR9810614A - Compositions of oil-in-water vaccines - Google Patents

Compositions of oil-in-water vaccines


Publication number
BR9810614A BR9810614-7A BR9810614A BR9810614A BR 9810614 A BR9810614 A BR 9810614A BR 9810614 A BR9810614 A BR 9810614A BR 9810614 A BR9810614 A BR 9810614A
Prior art keywords
Prior art date
Application number
Other languages
Portuguese (pt)
Nathalie Garcon
Patricia Marie Christine Momin
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GBGB9711990.3A priority Critical patent/GB9711990D0/en
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Priority to PCT/EP1998/003479 priority patent/WO1998056414A1/en
Publication of BR9810614A publication Critical patent/BR9810614A/en



    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/38Medical treatment of vector-borne diseases characterised by the agent
    • Y02A50/408Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa
    • Y02A50/411Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Plasmodium, i.e. Malaria
    • Y02A50/412Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Plasmodium, i.e. Malaria the medicinal preparation containing antigens or antibodies, e.g. vaccines, antisera


Patente de Invenção: <B>COMPOSIçõES DE VACINAS DE óLEO-EM-áGUA"<D>. A presente invenção refere-se a emulsões de óleo-em-água estáveis aprimoradas apresentando substancialmente um diâmetro para a gotícula de óleo de 300 a 600 nm e compreendendo triglicerídeos, e a seu uso como adjuvantes de vacinas. Patent of Invention. <B> compositions oil-in-water VACCINES "<D> The present invention relates to stable oil-in-water emulsions improved substantially having a diameter of 300 Oil droplet 600 nm and comprising triglycerides and to their use as vaccine adjuvants.
BR9810614-7A 1997-06-11 1998-06-03 Compositions of oil-in-water vaccines BR9810614A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB9711990.3A GB9711990D0 (en) 1997-06-11 1997-06-11 Vaccine
PCT/EP1998/003479 WO1998056414A1 (en) 1997-06-11 1998-06-03 Oil in water vaccine compositions

Publications (1)

Publication Number Publication Date
BR9810614A true BR9810614A (en) 2000-09-12



Family Applications (1)

Application Number Title Priority Date Filing Date
BR9810614-7A BR9810614A (en) 1997-06-11 1998-06-03 Compositions of oil-in-water vaccines

Country Status (17)

Country Link
EP (1) EP0999852A1 (en)
JP (1) JP2002504106A (en)
KR (1) KR20010013644A (en)
CN (1) CN1260723A (en)
AR (1) AR012959A1 (en)
AU (1) AU728759B2 (en)
BR (1) BR9810614A (en)
CA (1) CA2293444A1 (en)
CO (1) CO4940401A1 (en)
GB (1) GB9711990D0 (en)
HU (1) HU0004001A3 (en)
IL (1) IL133126D0 (en)
NO (1) NO996133L (en)
PL (1) PL337488A1 (en)
TR (1) TR199903048T2 (en)
WO (1) WO1998056414A1 (en)
ZA (1) ZA9804969B (en)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
US8221761B1 (en) * 1999-02-26 2012-07-17 Novartis Ag Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing CG motifs
PL211151B1 (en) 2000-10-18 2012-04-30 Glaxosmithkline Biologicals S.A. Vaccines
ES2228497T3 (en) 1999-04-19 2005-04-16 Glaxosmithkline Biologicals S.A. adjuvant composition comprising saponin and an immunostimulatory oligonucleotide.
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
HU0201220A3 (en) * 1999-05-13 2004-07-28 Wyeth Holdings Corp Madison Adjuvant combination formulations
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
DK1227837T3 (en) 1999-10-22 2008-09-15 Aventis Pasteur A method for introduction and / or enhancing an immune response to a tumor antigen
DK1282702T3 (en) 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogenic polypeptides which are encoded by the mini-CAKE genes, and uses thereof
MY134424A (en) * 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
EP1435908A4 (en) * 2001-09-13 2006-03-15 Korea Inst Sci & Tech Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof
JP4726485B2 (en) * 2002-08-02 2011-07-20 大日本住友製薬株式会社 Bacterial cell wall skeleton component formulation
CA2502268A1 (en) 2002-10-23 2004-05-06 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
GB0411411D0 (en) * 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
DE602005025342D1 (en) 2004-05-28 2011-01-27 Glaxosmithkline Biolog Sa Vaccine compositions with virosome and a saponin-adjuvanted
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
MX2007011775A (en) 2005-03-23 2008-03-11 Glaxosmithkline Biolog Sa Composition.
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
MY148141A (en) 2005-12-22 2013-03-15 Glaxosmithkline Biolog Sa Vaccine
EP2476433A1 (en) 2006-03-30 2012-07-18 GlaxoSmithKline Biologicals S.A. Immunogenic composition
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
US10138279B2 (en) 2006-04-13 2018-11-27 Regents Of The University Of Michigan Compositions and methods for Bacillus anthracis vaccination
US9839685B2 (en) 2006-04-13 2017-12-12 The Regents Of The University Of Michigan Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
JP5639760B2 (en) 2006-07-17 2014-12-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Influenza vaccine
NZ574239A (en) 2006-07-18 2011-12-22 Glaxosmithkline Biolog Sa Hybrid fusion proteins for malaria vaccines
WO2008012538A2 (en) 2006-07-25 2008-01-31 The Secretary Of State For Defence Live vaccine strains of francisella
PT2068918E (en) 2006-09-26 2012-08-06 Infectious Disease Res Inst Vaccine composition containing synthetic adjuvant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
TW200908994A (en) 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
AU2007318026B2 (en) 2006-11-03 2013-04-18 Merck Sharp & Dohme (Holdings) Pty Ltd Canine Lyme disease vaccine
LT2137210T (en) 2007-03-02 2016-12-27 Glaxosmithkline Biologicals Sa Novel method and compositions
US9610340B2 (en) 2007-06-26 2017-04-04 Glaxosmithkline Biologicals, S.A. Vaccine comprising Streptococcus pneumoniae capsular polysaccharide conjugates
BRPI0815199A2 (en) 2007-08-13 2015-03-31 Glaxosmithkline Biolog Sa Use of an antigen derived from plasmodium falciparum circumsporozyte protein
PT2227483T (en) 2007-12-19 2017-06-21 Henry M Jackson Found Advancement Military Medicine Inc Soluble forms of hendra and nipah virus f glycoprotein and uses thereof
US8877208B2 (en) 2008-05-23 2014-11-04 The Regents Of The University Of Michigan Multivalent nanoemulsion vaccines
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
CN102223876A (en) 2008-09-26 2011-10-19 纳米生物公司 Nanoemulsion therapeutic compositions and methods of using the same
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
EA201500910A1 (en) 2009-02-10 2016-04-29 Новартис Аг Vaccines against flu with reduced number of squales
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
US8668911B2 (en) 2009-05-14 2014-03-11 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
CN102481312B (en) 2009-06-05 2015-07-15 传染性疾病研究院 Synthetic Glucopyranosyl Lipid Adjuvants
ES2566646T3 (en) 2009-06-16 2016-04-14 The Regents Of The University Of Michigan Nanoemulsion vaccines
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
DE102009056883B4 (en) * 2009-12-03 2012-08-16 Novartis Ag Vaccine adjuvants and to improved processes for the preparation thereof
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
CA2794558A1 (en) 2010-03-26 2011-09-29 Patricia Bourguignon Hiv vaccine
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
AU2011310838B2 (en) 2010-09-27 2015-11-05 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
BR112013007308A2 (en) 2010-09-27 2016-07-05 Glaxosmithkline Biolog Sa Vaccine
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
EA201391011A1 (en) 2011-01-06 2014-08-29 Бионор Иммуно Ас Monomeric and multimeric immunogenic peptides
SG194083A1 (en) 2011-04-08 2013-11-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
CN108424449A (en) 2011-09-16 2018-08-21 Ucb医药有限公司 Neutralising antibodies to the major exotoxins TcdA and TcdB of Clostridium difficile
WO2013074501A1 (en) 2011-11-14 2013-05-23 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
EP2788477A2 (en) 2011-12-07 2014-10-15 Institut Pasteur Identification of a swine parecho-like virus and applications
WO2013119856A1 (en) 2012-02-07 2013-08-15 Infectious Disease Research Institute Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
PL2850431T3 (en) 2012-05-16 2018-09-28 Immune Design Corp. Vaccines for hsv-2
EP2859011A1 (en) 2012-06-06 2015-04-15 Bionor Immuno AS Peptides derived from viral proteins for use as immunogens and dosage reactants
CN104812408A (en) 2012-07-24 2015-07-29 赛诺菲巴斯德有限公司 Vaccine compositions for prevention against dengue virus infection
JP2015524421A (en) 2012-07-24 2015-08-24 サノフィ・パスツールSanofipasteur vaccine composition
US9982034B2 (en) 2012-10-24 2018-05-29 Platelet Targeted Therapeutics, Llc Platelet targeted treatment
BR112015012515A2 (en) 2012-11-30 2017-09-12 Sanofi Pasteur methods for antibody induction
AU2014253791B2 (en) 2013-04-18 2019-05-02 Immune Design Corp. GLA monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
JP6306700B2 (en) 2013-11-01 2018-04-04 ユニバーシティ オブ オスロUniversity of Oslo Modified albumin and use thereof
WO2015070207A2 (en) 2013-11-11 2015-05-14 The Government Of The United States, As Represented By The Secretary Of The Army Ama-1 epitopes, antibodies, compositions, and methods of making and using the same
WO2015071769A2 (en) 2013-11-13 2015-05-21 University Of Oslo Outer membrane vesicles and uses thereof
WO2015071763A2 (en) 2013-11-15 2015-05-21 Oslo Universitetssykehus Hf Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
EP3071228A2 (en) 2013-11-20 2016-09-28 La Jolla Institute for Allergy and Immunology Pan pollen immunogens and methods and uses thereof for immune response modulation
WO2015077442A2 (en) 2013-11-20 2015-05-28 La Jolla Institute For Allergy And Immunology Grass pollen immunogens and methods and uses for immune response modulation
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
US20160030459A1 (en) 2014-01-21 2016-02-04 Immune Design Corp. Compositions and methods for treating allergic conditions
WO2015131053A1 (en) 2014-02-28 2015-09-03 Alk-Abelló A/S Polypeptides derived from phl p and methods and uses thereof for immune response modulation
KR101696514B1 (en) * 2014-08-18 2017-01-24 서울대학교산학협력단 Temperature Sensitive Mycobacterial strain and its use as vaccine against mycobacterial infection disease
AR102548A1 (en) 2014-11-07 2017-03-08 Takeda Vaccines Inc Disease vaccines hands, feet and mouth and methods of manufacture and use
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
WO2017158421A1 (en) 2016-03-14 2017-09-21 University Of Oslo Anti-viral engineered immunoglobulins
WO2017158426A1 (en) 2016-03-14 2017-09-21 University Of Oslo Engineered immunoglobulins with altered fcrn binding
EP3471761A2 (en) 2016-06-21 2019-04-24 University Of Oslo Hla binding vaccine moieties and uses thereof
CA3034124A1 (en) 2016-08-23 2018-03-01 Glaxosmithkline Biologicals Sa Fusion peptides with antigens linked to short fragments of invariant chain (cd74)
EP3518966A1 (en) 2016-09-29 2019-08-07 GlaxoSmithKline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
WO2018232257A1 (en) 2017-06-15 2018-12-20 Infectious Disease Research Institute Nanostructured lipid carriers and stable emulsions and uses thereof
WO2019048936A1 (en) 2017-09-07 2019-03-14 University Of Oslo Vaccine molecules
WO2019048928A1 (en) 2017-09-07 2019-03-14 University Of Oslo Vaccine molecules
WO2019090233A2 (en) 2017-11-03 2019-05-09 Takeda Vaccines, Inc. Method for inactivating zika virus and for determining the completeness of inactivation
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011700A1 (en) * 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines

Also Published As

Publication number Publication date
HU0004001A3 (en) 2001-07-30
HU0004001A2 (en) 2001-03-28
CN1260723A (en) 2000-07-19
GB9711990D0 (en) 1997-08-06
PL337488A1 (en) 2000-08-28
AU8336598A (en) 1998-12-30
CA2293444A1 (en) 1998-12-17
NO996133D0 (en) 1999-12-10
CO4940401A1 (en) 2000-07-24
AU728759B2 (en) 2001-01-18
JP2002504106A (en) 2002-02-05
KR20010013644A (en) 2001-02-26
EP0999852A1 (en) 2000-05-17
TR199903048T2 (en) 2000-08-21
WO1998056414A1 (en) 1998-12-17
IL133126D0 (en) 2001-03-19
AR012959A1 (en) 2000-11-22
ZA9804969B (en) 1999-12-09
NO996133L (en) 2000-01-26

Similar Documents

Publication Publication Date Title
ES2141393T3 (en) Using oligonucleotides substituted at position 2 &#39;suppressive regulation of gene expression.
BR0015188A (en) pharmaceutical compositions
CR8086A (en) 1,2,4-oxadiazole compounds of benzoic acid and its use for suppression of nonsense mutations
PA8459901A1 (en) Resorcinol derivatives
ES2181633T3 (en) Emulsions water-in-oil emulsions containing at least one insoluble organic UV filter and non filter organomodified silicone.
BR9917661B1 (en) GAS inspiratàrio device for driving a ventilator and a patient up to conduct gas from the patient exalaÇço.
BR9809945A (en) non-hazardous pest control
BR9809791A (en) phosphate aminoalkyl glucosamine compounds and their use as auxiliary and immune effectors
BR0014282A (en) vaccines
BR0112584A (en) benzidroxâmicos oxygenated esters of 4-iodophenylamino acids
BR9713462A (en) Methods for producing carotenoid compounds in special oils and plant seeds.
BR9912726B1 (en) amide derivative, pharmaceutical composition and use of an amide derivative.
BR9916857A (en) Heteroaryl diarylamines 4
DK1283700T3 (en) Sustained release pharmaceutical compositions for the parenteral administration of biologically active hydrophilic compounds
ES2185953T3 (en) Microemulsion compositions for insect control.
NO316963B1 (en) Use of an unsaturated fatty alcohol to stabilize the macrolide in a pharmaceutical composition and a topical formulation
BR0113822A (en) Vaccine
ITBO980572D0 (en) Device for the protection after the &#39;use of a hypodermic needle, cularly parts of the butterfly type.
GT199700095A (en) 6,5-heterobicyclic derivatives substituted.
BR9909492A (en) pulmonary and nasal release of raloxifene
BR0104743A (en) Composition for keratinous fibers oxidation dye comprising an amphiphile catiÈnico polymer, a fatty alcohol oxyalkylenated or glycerolated and a hydroxylated solvent composition ready for use for the oxidation dyeing of keratinous fibers, dyeing process for keratinous fibers and device several compartments or kit for dyeing keratin fibers, non-oxidizing
BR0313154A (en) New immunogenic lipopeptides comprising T-helper epitopes cell and B cell
ES2169759T3 (en) Process for preparing emulsions and microcapsules containing natural oil and use thereof.
SE0001899D0 (en) New compounds

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 5A,6A,7A,8A E 9A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1909 DE 07/08/2007.